Wednesday, November 18, 2026
RSS

Pharmaceutical

Q32 Bio Slides as Conference Commentary Raises Phase 3 Volatility

Q32 Bio shares fell 2.9% premarket after Phase 3 commentary at the Jefferies conference, underscoring the risks of small-cap biotech trading.

November 18, 2026
Pharmaceutical

Biogen’s Mixed Alzheimer’s Data Leaves Investors Weighing CELIA’s Signal

Biogen’s two-year CELIA data showed broad clinical improvement at 60 mg, but the MMSE exception leaves investors weighing a mixed Alzheimer’s signal.

Nov 18
Pharmaceutical

Bristol Myers Squibb’s KarXT Data Puts Schizophrenia Growth Story in Focus

Preliminary KarXT data puts Bristol Myers Squibb’s psychiatry pipeline under the microscope, with investors watching for evidence that could shape fut…

Nov 18
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Pharmaceutical

GSK Wins FDA Approval for Nelkarmi After $10.6 Billion Nuvalent Acquisition

Nelkarmi’s FDA approval gives GSK an early validation point for its $10.6 billion Nuvalent acquisition and strengthens i…

Nov 18, 2026
Pharmaceutical

Rythm Pharmaceuticals Jumps on Reported $150 Offer From Eli Lilly With CVR

Rythm Pharmaceuticals gained after a report of a $150-per-share Eli Lilly offer with a CVR, creating premium potential b…

Nov 18, 2026
Pharmaceutical

Cardiff Oncology’s Phase III Push Puts Trial Durability in the Spotlight

Cardiff Oncology’s UBS conference update puts its Phase III timeline—and the durability question—at the center of the CR…

Nov 17, 2026
Pharmaceutical

Roche’s FDA Approval Adds Momentum to Its Advanced Breast Cancer Franchise

Roche’s FDA approval for an advanced breast cancer pill gives North American healthcare investors a fresh regulatory cat…

Nov 17, 2026
Pharmaceutical

AstraZeneca’s Two FDA Approvals Expand Its U.S. Growth Pipeline

AstraZeneca’s two U.S. FDA approvals broaden its commercial portfolio and give investors a fresh signal on pipeline exec…

Nov 17, 2026
Pharmaceutical

Acadia’s Mixed Alzheimer’s Psychosis Readout Keeps ACAD Investors Focused on Phase 3

Acadia’s RADIANT study missed its primary endpoint but hit a key secondary endpoint, leaving ACAD with near-term uncerta…

Nov 17, 2026
Pharmaceutical

Aytu BioPharma Buyout Sets $2.70 Per-Share Target for Deal Arbitrage Traders

Rosemont’s proposed acquisition of Aytu BioPharma establishes a fixed $2.70-per-share reference point for AYTU deal anal…

Nov 17, 2026
Pharmaceutical

Eli Lilly’s $1.5 Billion Calytrix Deal Signals a Push Beyond Obesity Drugs

Eli Lilly’s up-to-$1.5 billion Calytrix Bio acquisition points to broader pipeline ambitions as biotech consolidation co…

Nov 17, 2026
Pharmaceutical

MiniMed Stock Gains as FDA Clearance Puts Tubeless Pump in the Spotlight

MiniMed stock gained after FDA clearance of its tubeless insulin pump, giving the $5.29 billion company a potential near…

Nov 16, 2026